{
  "prompt": {
    "prompt": "Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\n\nFor each recommendation, specify:\n1. The type of recommendation:\n   - Additional information needed (history/examination/investigations)\n   - Improved patient advice (options/statistics/patient information)\n   - Different management plan\n2. The specific recommendation\n3. The reason for the recommendation (referencing the guideline)\n\nCategorize each recommendation by importance:\n- Very Important: Critical for patient safety or guideline compliance\n- Somewhat Important: Significant for optimal care but not critical\n- Less Important: Would improve care but not essential\n- Unimportant: Minor suggestions that could be considered\n\nFormat the response as follows:\n\n### Very Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Somewhat Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Less Important Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\n### Unimportant Recommendations\n[Type] - [Specific recommendation]\nReason: [Reference to guideline ID and relevant section]\n\nClinical Note:\n**Dictation: Clinical Interaction – Abnormal Uterine Bleeding**  **Patient Details:**  \n- Name: [Fictional Name] Jane Doe  \n- Age: 36  \n- BMI: 18.9 (weight 52 kg, height 1.65 m)  \n- Gravida: 1, Para: 1 (prior full-term vaginal delivery)  \nLast Menstrual Period (LMP): 2 weeks ago (currently mid-cycle)  \n- Contraception: None currently  **History of Presenting Complaint:**  \nMs. Doe presents with a 4-month history of irregular menstrual bleeding. She reports episodes of heavy bleeding lasting 7–10 days, occurring every 2–3 weeks, with associated fatigue. She denies intermenstrual spotting but admits to occasional cramping. No history of post-coital bleeding. She has not been sexually active in the past year.  **Relevant Medical History:**  \nNo known bleeding disorders or thyroid dysfunction.  \nNo prior gynecological procedures (e.g., hysteroscopy, D&C).  \nNo history of fibroids or endometriosis.  \nNo chronic medical conditions.  **Medications & Allergies:**  \nOccasional ibuprofen for cramps (no regular medications).  \nNo known drug allergies.  **Social History:**  \nNon-smoker, occasional alcohol (1–2 units/week).  \nWorks as a teacher; moderate stress levels reported.  **Examination Findings:**  \n- General appearance: Pale conjunctivae (possible anemia).  \n- Abdomen: Soft, non-tender, no palpable masses.  \n- Speculum exam: Cervix appears normal, no visible lesions.  \n- Bimanual exam: Uterus anteverted, normal size, no adnexal tenderness.  **Notable Omissions (for testing purposes):**  \nNo documented assessment of iron studies or hemoglobin.  \nNo inquiry about family history of gynecological malignancies.  \nNo discussion of prior Pap smear history or HPV vaccination status.  \nPelvic ultrasound not yet performed.  **Impression:**  \nAbnormal uterine bleeding (AUB) in a premenopausal patient—differential includes ovulatory dysfunction (e.g., PCOS, thyroid disorder), endometrial polyp, or early perimenopausal changes.  **Management Plan:**  \n1. **Investigations:**  \n   Full blood count (FBC) to assess for anemia.  \n   TSH and prolactin to evaluate endocrine causes.  \n   Pelvic ultrasound to rule out structural pathology.  \n   (No endometrial biopsy arranged at this stage.)  2. **Symptomatic Relief:**  \n   Trial of tranexamic acid during heavy bleeding.  \n   Consider combined oral contraceptive pill (COCP) for cycle regulation if no contraindications.  3. **Follow-Up:**  \n   Review in 6 weeks with investigation results.  \n   If bleeding worsens or anemia confirmed, escalate to gynecology referral.  **Counseling Provided:**  \nReassured that AUB is common but requires evaluation.  \nAdvised to monitor bleeding patterns and report syncope or severe fatigue.  **Dictated by:** Dr. [Fictional Name] Smith  \n**Date:** [Fictional Date]  --*Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.*\n\n\n\nGuideline:\n[ID] bashh-2014-mx-of-vulval-conditions-pdf\nTitle: BASHH - 2014 - Mx of Vulval Conditions.pdf\nContent:  2014 UK National Guideline on the Management of Vulval Conditions\n\nNew in the 2014 Guidelines:\n- General advice for the management of vulval disorders\n- Onward referral guidelines\n- Vulval lichen simplex\n- Vulval psoriasis\n- Use of calcineurin inhibitors\n\nObjectives:\n- Recommendations on the management of vulval disorders\n- Concentrates on a select group of conditions\n- Offers guidance for onward referral\n\nGeneral Advice for all vulval conditions:\n- Avoid irritants\n- Inform GP\n- Consider STI screening\n- Assess for sexual dysfunction\n\nVulval lichen sclerosus:\n- Symptoms include itch, soreness, dyspareunia\n- Signs include pale, white areas, fissuring, erosions\n- Complications may include squamous cell carcinoma\n- Diagnosis through clinical appearance and histology\n- Treatment with ultra-potent topical steroids\n\nVulval lichen planus:\n- Symptoms include itch, soreness, dyspareunia\n- Signs include different lesions types\n- Complications may include scarring and carcinoma\n- Diagnosis through clinical appearance and histology\n- Treatment with biopsy and topical steroids\n\nSmall risk of neoplastic change. Recommended Regimen: Ultrapotent topical steroids like Clobetasol proprionate. Maintenance treatment may be required with weaker steroid preparations. Vaginal corticosteroids may be used in more severe cases. Alternative regimens may include ultra-potent topical steroids with antibacterial and antifungal properties. Topical steroids are safe to use during pregnancy or breastfeeding. Referral to a vulval clinic is recommended for erosive disease or recalcitrant cases. Follow-up at 2-3 months is advised. Biopsy should be performed in non-responsive cases. \n\nVulval eczema: Avoidance of precipitating factors is recommended. Use of emollient soap substitute and topical corticosteroids are advised. Follow-up as clinically required. \n\nLichen simplex: Avoidance of precipitating factors and use of emollient soap substitute are recommended. Topical corticosteroids and anxiolytic antihistamines may be used. Cognitive behavioral therapy may be helpful. Follow-up as clinically required. \n\nVulval psoriasis: Avoidance of irritating factors and use of emollient soap substitute are recommended. Topical corticosteroids and coal-tar preparations may be used. Follow-up as clinically required. \n\nVulval intraepithelial neoplasia (VIN): Referral for colposcopy is recommended. Treatment options include local excision, imiquimod cream, or vulvectomy. Follow-up is mandatory. \n\nVulval pain: Vulvodynia is defined as vulvar discomfort without visible findings. Treatment depends on the type of vulvodynia.\n\nAetiology: Likely multifactorial, with a history of recurrent vulvovaginal candidiasis as a common feature.\n\nClinical Features: Vulval pain, focal tenderness, no signs of acute inflammation.\n\nComplications: Sexual dysfunction, psychological morbidity.\n\nDiagnosis: Clinical diagnosis based on history and examination.\n\nManagement: Exclude other treatable causes before further investigation. Multidisciplinary approach to patient care recommended.\n\nTreatment: Avoid irritating factors, use emollient soap substitute, consider topical local anaesthetics with caution. Physical therapies, cognitive behaviour therapy, pain modifiers, and surgery may be options.\n\nFollow-up: As clinically required, long-term follow-up and psychological support may be necessary.\n\nUnprovoked Vulvodynia: Aetiology unknown, managed as a chronic pain syndrome.\n\nClinical Features: Longstanding unexplained pain, may be associated with urinary symptoms.\n\nComplications: Sexual dysfunction, psychological morbidity.\n\nDiagnosis: Clinical diagnosis after excluding other causes.\n\nManagement: Exclude other treatable causes before further investigation. Multidisciplinary approach to patient care recommended.\n\nTreatment: Use emollient soap substitute, consider pain modifiers like tricyclic antidepressants. Referral to a pain clinic may be necessary for treatment-resistant cases.\n\nFollow-up: As clinically required.\n\nGuidelines for the management of Vulvodynia. Long-term results of therapeutic approach to provoked vestibulodynia. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia. Transcutaneous electrical nerve stimulation to treat vestibulodynia. Use of Amielle Vaginal Trainers in the treatment of Vestibulodynia. Psychological predictors of treatment outcome for provoked vestibulodynia. Long-term follow up of posterior vestibulectomy for treating vulvar vestibulitis. Treatment of vulvodynia with tricyclic antidepressants. Evaluation of gabapentin in the treatment of generalized vulvodynia. Pregabalin-induced remission in a woman with vulvodynia. A randomized clinical trial for women with vulvodynia: Cognitive-behavioral therapy vs. supportive psychotherapy. Acupuncture for vulvodynia.",
    "system_prompt": "You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.",
    "guideline_id": "bashh-2014-mx-of-vulval-conditions-pdf",
    "guideline_title": "BASHH - 2014 - Mx of Vulval Conditions.pdf"
  },
  "response": "### Analysis of Clinical Note vs. Guideline  \n\nThe provided clinical note focuses on **abnormal uterine bleeding (AUB)**, while the referenced guideline (**BASHH - 2014 - Management of Vulval Conditions**) pertains to **vulval disorders** (e.g., lichen sclerosus, vulvodynia, psoriasis). Since these are distinct clinical entities, there is **no direct overlap** between the note and the guideline.  \n\n### Key Observations:  \n1. The guideline does **not** apply to AUB, endometrial pathology, or hormonal investigations.  \n2. The guideline focuses on **vulval dermatoses, pain syndromes, and neoplastic conditions**, none of which are mentioned in the note.  \n3. The clinical note appropriately addresses AUB with a **relevant workup (FBC, TSH, ultrasound)** and **management (tranexamic acid, COCP)**.  \n\n### Possible Minor Considerations (If Vulval Symptoms Were Present):  \nIf the patient had **concurrent vulval symptoms** (e.g., itching, pain, lesions), the guideline would recommend:  \n- **STI screening** (if sexually active)  \n- **Avoidance of irritants** (soaps, tight clothing)  \n- **Topical steroids** (if lichen sclerosus/planus suspected)  \n- **Referral to a vulval clinic** for persistent/recalcitrant cases  \n\nHowever, since the note does **not** describe vulval complaints, **no changes are necessary** to align with this guideline.  \n\n### Final Assessment:  \n- **No modifications needed**—the clinical note appropriately follows AUB management principles.  \n- If vulval symptoms were present, a **separate assessment** using the BASHH guideline would be required.  \n\nWould you like an analysis against a **different guideline** (e.g., AUB, PCOS, or endometrial evaluation)?",
  "endpoint": "analyzeNoteAgainstGuideline",
  "timestamp": "2025-06-09T03-00-39",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Please analyze the clinical note against the provided guideline and suggest improvements to better align with the guideline recommendations.\\n\\nFor each recommendation, specify:\\n1. The type of recommendation:\\n   - Additional information needed (history/examination/investigations)\\n   - Improved patient advice (options/statistics/patient information)\\n   - Different management plan\\n2. The specific recommendation\\n3. The reason for the recommendation (referencing the guideline)\\n\\nCategorize each recommendation by importance:\\n- Very Important: Critical for patient safety or guideline compliance\\n- Somewhat Important: Significant for optimal care but not critical\\n- Less Important: Would improve care but not essential\\n- Unimportant: Minor suggestions that could be considered\\n\\nFormat the response as follows:\\n\\n### Very Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Somewhat Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Less Important Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\n### Unimportant Recommendations\\n[Type] - [Specific recommendation]\\nReason: [Reference to guideline ID and relevant section]\\n\\nClinical Note:\\n**Dictation: Clinical Interaction – Abnormal Uterine Bleeding**  **Patient Details:**  \\n- Name: [Fictional Name] Jane Doe  \\n- Age: 36  \\n- BMI: 18.9 (weight 52 kg, height 1.65 m)  \\n- Gravida: 1, Para: 1 (prior full-term vaginal delivery)  \\nLast Menstrual Period (LMP): 2 weeks ago (currently mid-cycle)  \\n- Contraception: None currently  **History of Presenting Complaint:**  \\nMs. Doe presents with a 4-month history of irregular menstrual bleeding. She reports episodes of heavy bleeding lasting 7–10 days, occurring every 2–3 weeks, with associated fatigue. She denies intermenstrual spotting but admits to occasional cramping. No history of post-coital bleeding. She has not been sexually active in the past year.  **Relevant Medical History:**  \\nNo known bleeding disorders or thyroid dysfunction.  \\nNo prior gynecological procedures (e.g., hysteroscopy, D&C).  \\nNo history of fibroids or endometriosis.  \\nNo chronic medical conditions.  **Medications & Allergies:**  \\nOccasional ibuprofen for cramps (no regular medications).  \\nNo known drug allergies.  **Social History:**  \\nNon-smoker, occasional alcohol (1–2 units/week).  \\nWorks as a teacher; moderate stress levels reported.  **Examination Findings:**  \\n- General appearance: Pale conjunctivae (possible anemia).  \\n- Abdomen: Soft, non-tender, no palpable masses.  \\n- Speculum exam: Cervix appears normal, no visible lesions.  \\n- Bimanual exam: Uterus anteverted, normal size, no adnexal tenderness.  **Notable Omissions (for testing purposes):**  \\nNo documented assessment of iron studies or hemoglobin.  \\nNo inquiry about family history of gynecological malignancies.  \\nNo discussion of prior Pap smear history or HPV vaccination status.  \\nPelvic ultrasound not yet performed.  **Impression:**  \\nAbnormal uterine bleeding (AUB) in a premenopausal patient—differential includes ovulatory dysfunction (e.g., PCOS, thyroid disorder), endometrial polyp, or early perimenopausal changes.  **Management Plan:**  \\n1. **Investigations:**  \\n   Full blood count (FBC) to assess for anemia.  \\n   TSH and prolactin to evaluate endocrine causes.  \\n   Pelvic ultrasound to rule out structural pathology.  \\n   (No endometrial biopsy arranged at this stage.)  2. **Symptomatic Relief:**  \\n   Trial of tranexamic acid during heavy bleeding.  \\n   Consider combined oral contraceptive pill (COCP) for cycle regulation if no contraindications.  3. **Follow-Up:**  \\n   Review in 6 weeks with investigation results.  \\n   If bleeding worsens or anemia confirmed, escalate to gynecology referral.  **Counseling Provided:**  \\nReassured that AUB is common but requires evaluation.  \\nAdvised to monitor bleeding patterns and report syncope or severe fatigue.  **Dictated by:** Dr. [Fictional Name] Smith  \\n**Date:** [Fictional Date]  --*Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.*\\n\\n\\n\\nGuideline:\\n[ID] bashh-2014-mx-of-vulval-conditions-pdf\\nTitle: BASHH - 2014 - Mx of Vulval Conditions.pdf\\nContent:  2014 UK National Guideline on the Management of Vulval Conditions\\n\\nNew in the 2014 Guidelines:\\n- General advice for the management of vulval disorders\\n- Onward referral guidelines\\n- Vulval lichen simplex\\n- Vulval psoriasis\\n- Use of calcineurin inhibitors\\n\\nObjectives:\\n- Recommendations on the management of vulval disorders\\n- Concentrates on a select group of conditions\\n- Offers guidance for onward referral\\n\\nGeneral Advice for all vulval conditions:\\n- Avoid irritants\\n- Inform GP\\n- Consider STI screening\\n- Assess for sexual dysfunction\\n\\nVulval lichen sclerosus:\\n- Symptoms include itch, soreness, dyspareunia\\n- Signs include pale, white areas, fissuring, erosions\\n- Complications may include squamous cell carcinoma\\n- Diagnosis through clinical appearance and histology\\n- Treatment with ultra-potent topical steroids\\n\\nVulval lichen planus:\\n- Symptoms include itch, soreness, dyspareunia\\n- Signs include different lesions types\\n- Complications may include scarring and carcinoma\\n- Diagnosis through clinical appearance and histology\\n- Treatment with biopsy and topical steroids\\n\\nSmall risk of neoplastic change. Recommended Regimen: Ultrapotent topical steroids like Clobetasol proprionate. Maintenance treatment may be required with weaker steroid preparations. Vaginal corticosteroids may be used in more severe cases. Alternative regimens may include ultra-potent topical steroids with antibacterial and antifungal properties. Topical steroids are safe to use during pregnancy or breastfeeding. Referral to a vulval clinic is recommended for erosive disease or recalcitrant cases. Follow-up at 2-3 months is advised. Biopsy should be performed in non-responsive cases. \\n\\nVulval eczema: Avoidance of precipitating factors is recommended. Use of emollient soap substitute and topical corticosteroids are advised. Follow-up as clinically required. \\n\\nLichen simplex: Avoidance of precipitating factors and use of emollient soap substitute are recommended. Topical corticosteroids and anxiolytic antihistamines may be used. Cognitive behavioral therapy may be helpful. Follow-up as clinically required. \\n\\nVulval psoriasis: Avoidance of irritating factors and use of emollient soap substitute are recommended. Topical corticosteroids and coal-tar preparations may be used. Follow-up as clinically required. \\n\\nVulval intraepithelial neoplasia (VIN): Referral for colposcopy is recommended. Treatment options include local excision, imiquimod cream, or vulvectomy. Follow-up is mandatory. \\n\\nVulval pain: Vulvodynia is defined as vulvar discomfort without visible findings. Treatment depends on the type of vulvodynia.\\n\\nAetiology: Likely multifactorial, with a history of recurrent vulvovaginal candidiasis as a common feature.\\n\\nClinical Features: Vulval pain, focal tenderness, no signs of acute inflammation.\\n\\nComplications: Sexual dysfunction, psychological morbidity.\\n\\nDiagnosis: Clinical diagnosis based on history and examination.\\n\\nManagement: Exclude other treatable causes before further investigation. Multidisciplinary approach to patient care recommended.\\n\\nTreatment: Avoid irritating factors, use emollient soap substitute, consider topical local anaesthetics with caution. Physical therapies, cognitive behaviour therapy, pain modifiers, and surgery may be options.\\n\\nFollow-up: As clinically required, long-term follow-up and psychological support may be necessary.\\n\\nUnprovoked Vulvodynia: Aetiology unknown, managed as a chronic pain syndrome.\\n\\nClinical Features: Longstanding unexplained pain, may be associated with urinary symptoms.\\n\\nComplications: Sexual dysfunction, psychological morbidity.\\n\\nDiagnosis: Clinical diagnosis after excluding other causes.\\n\\nManagement: Exclude other treatable causes before further investigation. Multidisciplinary approach to patient care recommended.\\n\\nTreatment: Use emollient soap substitute, consider pain modifiers like tricyclic antidepressants. Referral to a pain clinic may be necessary for treatment-resistant cases.\\n\\nFollow-up: As clinically required.\\n\\nGuidelines for the management of Vulvodynia. Long-term results of therapeutic approach to provoked vestibulodynia. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia. Transcutaneous electrical nerve stimulation to treat vestibulodynia. Use of Amielle Vaginal Trainers in the treatment of Vestibulodynia. Psychological predictors of treatment outcome for provoked vestibulodynia. Long-term follow up of posterior vestibulectomy for treating vulvar vestibulitis. Treatment of vulvodynia with tricyclic antidepressants. Evaluation of gabapentin in the treatment of generalized vulvodynia. Pregabalin-induced remission in a woman with vulvodynia. A randomized clinical trial for women with vulvodynia: Cognitive-behavioral therapy vs. supportive psychotherapy. Acupuncture for vulvodynia.\",\n  \"system_prompt\": \"You are a medical guidelines compliance checker. Your task is to analyze if the given clinical note follows the specified guideline and suggest improvements.\",\n  \"guideline_id\": \"bashh-2014-mx-of-vulval-conditions-pdf\",\n  \"guideline_title\": \"BASHH - 2014 - Mx of Vulval Conditions.pdf\"\n}\n\nA: ### Analysis of Clinical Note vs. Guideline  \n\nThe provided clinical note focuses on **abnormal uterine bleeding (AUB)**, while the referenced guideline (**BASHH - 2014 - Management of Vulval Conditions**) pertains to **vulval disorders** (e.g., lichen sclerosus, vulvodynia, psoriasis). Since these are distinct clinical entities, there is **no direct overlap** between the note and the guideline.  \n\n### Key Observations:  \n1. The guideline does **not** apply to AUB, endometrial pathology, or hormonal investigations.  \n2. The guideline focuses on **vulval dermatoses, pain syndromes, and neoplastic conditions**, none of which are mentioned in the note.  \n3. The clinical note appropriately addresses AUB with a **relevant workup (FBC, TSH, ultrasound)** and **management (tranexamic acid, COCP)**.  \n\n### Possible Minor Considerations (If Vulval Symptoms Were Present):  \nIf the patient had **concurrent vulval symptoms** (e.g., itching, pain, lesions), the guideline would recommend:  \n- **STI screening** (if sexually active)  \n- **Avoidance of irritants** (soaps, tight clothing)  \n- **Topical steroids** (if lichen sclerosus/planus suspected)  \n- **Referral to a vulval clinic** for persistent/recalcitrant cases  \n\nHowever, since the note does **not** describe vulval complaints, **no changes are necessary** to align with this guideline.  \n\n### Final Assessment:  \n- **No modifications needed**—the clinical note appropriately follows AUB management principles.  \n- If vulval symptoms were present, a **separate assessment** using the BASHH guideline would be required.  \n\nWould you like an analysis against a **different guideline** (e.g., AUB, PCOS, or endometrial evaluation)?\n\n--- Token Usage Report ---\nPrompt tokens: 1975\nCompletion tokens: 394\nTotal tokens: 2369\nEstimated cost: $0.001185",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 1975,
    "completion_tokens": 394,
    "total_tokens": 2369,
    "estimated_cost_usd": 0.0011845000000000002
  }
}